 ROCKVILLE, MD, Sept. 16, 2021 GLOBE NEWSWIRE -- MacroGenics, Inc. NASDAQ: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced results from Cohort A Part 1 of the Phase 23 MAHOGANY clinical trial of margetuximab. MARGENZA margetuximab-cmkb is approved in HER2 metastatic breast cancer and is being investigated as a potential first-line treatment for patients with HER2 gastric cancer GC or gastroesophageal junction GEJ cancer in combination with a checkpoint inhibitor, with or without chemotherapy. The dataset is available in a poster titled Margetuximab With Retifanlimab in HER2, PD-L1 First-Line UnresectableMetastatic Gastroesophageal Adenocarcinoma GEA: MAHOGANY Cohort A Poster 1379P at the 2021 European Society for Medical Oncology ESMO Virtual Conference taking place September 16-21, 2021. 